Kineta Announces New Research Agreement to Evaluate VISTA Biomarker ExpressionGlobeNewsWire • 09/18/23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/11/23
Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott DyllaGlobeNewsWire • 06/28/23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/23
Kineta, Inc. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 04/24/23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 04/20/23
Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023GlobeNewsWire • 04/17/23
Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid TumorsGlobeNewsWire • 04/12/23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/31/23
Kineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology TargetGlobeNewsWire • 03/06/23
Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory BoardGlobeNewsWire • 03/01/23